JP6158840B2 - ガレクチンのガラクトシド阻害剤 - Google Patents

ガレクチンのガラクトシド阻害剤 Download PDF

Info

Publication number
JP6158840B2
JP6158840B2 JP2014553715A JP2014553715A JP6158840B2 JP 6158840 B2 JP6158840 B2 JP 6158840B2 JP 2014553715 A JP2014553715 A JP 2014553715A JP 2014553715 A JP2014553715 A JP 2014553715A JP 6158840 B2 JP6158840 B2 JP 6158840B2
Authority
JP
Japan
Prior art keywords
galectin
methyl
bis
galactopyranosyl
sulfane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014553715A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015504909A (ja
JP2015504909A5 (enExample
Inventor
ニルソン，ウルフ
レフレル，ホーコン
ムコパディヤイ，バララム
ラージプート，ヴィシャル
Original Assignee
ガレクト・バイオテック・エイビイ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ガレクト・バイオテック・エイビイ filed Critical ガレクト・バイオテック・エイビイ
Publication of JP2015504909A publication Critical patent/JP2015504909A/ja
Publication of JP2015504909A5 publication Critical patent/JP2015504909A5/ja
Application granted granted Critical
Publication of JP6158840B2 publication Critical patent/JP6158840B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/01—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2014553715A 2012-01-25 2013-01-24 ガレクチンのガラクトシド阻害剤 Expired - Fee Related JP6158840B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12152413.6 2012-01-25
EP12152413.6A EP2620443A1 (en) 2012-01-25 2012-01-25 Novel galactoside inhibitors of galectins
PCT/EP2013/051339 WO2013110704A1 (en) 2012-01-25 2013-01-24 Novel galactoside inhibitors of galectins

Publications (3)

Publication Number Publication Date
JP2015504909A JP2015504909A (ja) 2015-02-16
JP2015504909A5 JP2015504909A5 (enExample) 2016-03-10
JP6158840B2 true JP6158840B2 (ja) 2017-07-05

Family

ID=47598867

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014553715A Expired - Fee Related JP6158840B2 (ja) 2012-01-25 2013-01-24 ガレクチンのガラクトシド阻害剤

Country Status (8)

Country Link
US (1) US9353141B2 (enExample)
EP (2) EP2620443A1 (enExample)
JP (1) JP6158840B2 (enExample)
CN (1) CN104066743B (enExample)
CA (1) CA2854986C (enExample)
ES (1) ES2559857T3 (enExample)
IN (1) IN2014DN05772A (enExample)
WO (1) WO2013110704A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
BR0015294A (pt) 1999-11-03 2003-07-15 Bristol Myers Squibb Co Método para tratamento da diabetes
US9243021B2 (en) 2012-10-31 2016-01-26 Galecto Biotech Ab Galactoside inhibitor of galectins
EP2919802A4 (en) * 2012-11-15 2016-09-14 Univ Tufts METHOD, COMPOSITIONS AND KITS FOR TREATING, MODULATING OR PREVENTING ANGIOGENESIS OR FIBROSIS IN A PATIENT USING A GALECTINE PROTEIN HEMMER
US12390486B2 (en) 2012-12-20 2025-08-19 Henry Ford Health System Method for treating diastolic heart failure by inhibiting galectin-3
JP2016507503A (ja) 2012-12-20 2016-03-10 ヘンリー フォード ヘルス システム ガレクチン−３を阻害することによる拡張期心不全を治療する方法
JP6735680B2 (ja) * 2014-07-09 2020-08-05 ガレクト バイオテック エービー ガレクチンの新規ハイブリッドガラクトシド阻害剤
CA2970062C (en) * 2015-01-30 2023-02-28 Galecto Biotech Ab Alpha-d-galactoside inhibitors of galectins
US20190367552A1 (en) * 2016-03-04 2019-12-05 Galectin Sciences, Llc Selenogalactoside compounds for the prevention and treatment of diseases associated with galectin and the use thereof
CN109563119A (zh) * 2016-07-12 2019-04-02 格莱克特生物技术公司 半乳糖凝集素的α-D-半乳糖苷抑制剂
CN109563120B (zh) * 2016-07-12 2022-12-02 格莱克特生物技术公司 半乳糖凝集素的α-D-半乳糖苷抑制剂
KR102626669B1 (ko) 2017-05-12 2024-01-17 갈랙틴 사이언시즈, 엘엘씨 질환의 예방 및 치료를 위한 화합물 및 이의 용도
US11548908B2 (en) 2017-12-29 2023-01-10 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3
CA3102155A1 (en) * 2018-06-29 2020-01-02 Glykos Biomedical Oy Conjugates
US11845771B2 (en) 2018-12-27 2023-12-19 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3
JP7547345B2 (ja) 2018-12-27 2024-09-09 グリコミメティクス， インコーポレイテッド ガレクチン－３阻害性ｃ－グリコシド
KR102863667B1 (ko) * 2019-08-09 2025-09-23 이도르시아 파마슈티컬스 리미티드 (2-아세트아미딜)티오-베타-d-갈락토피라노시드 유도체
US20230038373A1 (en) 2019-12-18 2023-02-09 Glykos Biomedical Oy Stabile conjugate
CN116270672B (zh) * 2023-02-27 2026-03-27 江苏科技大学 β-D-硫代葡萄糖钠盐在制备缓解或治疗急性肾损伤的药物中的应用
CZ2023132A3 (cs) 2023-04-04 2024-10-16 Ústav Chemických Procesů Av Čr, V. V. I. Komplexy ruthenia pro inhibici galektinů, způsob jejich výroby a jejich použití

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0100172D0 (sv) * 2001-01-22 2001-01-22 Ulf Nilsson New inhibitors against galectins
SE0401300D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel Galactoside Inhibitors of Galectins
SE0401301D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel 3-triazolyl-galactoside inhibitors of galectins
US8697862B2 (en) 2008-05-16 2014-04-15 Galecto Biotech Ab Synthesis of galactoside inhibitors
ES2652488T3 (es) 2009-04-28 2018-02-02 Galecto Biotech Ab Nuevos inhibidores de galactósidos de galectinas
IN2015DN02573A (enExample) 2012-10-31 2015-09-11 Galecto Biotech Ab

Also Published As

Publication number Publication date
US20140336146A1 (en) 2014-11-13
CN104066743B (zh) 2016-04-06
WO2013110704A1 (en) 2013-08-01
ES2559857T3 (es) 2016-02-16
EP2620443A1 (en) 2013-07-31
JP2015504909A (ja) 2015-02-16
CA2854986C (en) 2019-09-17
CA2854986A1 (en) 2013-08-01
EP2807176A1 (en) 2014-12-03
EP2807176B1 (en) 2015-12-30
CN104066743A (zh) 2014-09-24
IN2014DN05772A (enExample) 2015-04-10
US9353141B2 (en) 2016-05-31

Similar Documents

Publication Publication Date Title
JP2015504909A (ja) ガレクチンのガラクトシド阻害剤
ES2921500T3 (es) 1,1'-sulfanodiil-di-beta-d-galactopiranósidos como inhibidores de galectinas
US10800804B2 (en) Hybrid galactoside inhibitor of galectins
US8703720B2 (en) Galactoside inhibitors of galectins
US5750664A (en) Substituted liposaccharides useful in the treatment and prevention of endotoxemia
KR102626669B1 (ko) 질환의 예방 및 치료를 위한 화합물 및 이의 용도
JP2022524678A (ja) ガレクチンのα－Ｄ－ガラクトシド阻害剤
JP2020122021A (ja) ガレクチンの新規なガラクトシド阻害剤
KR102346913B1 (ko) 갈렉틴과 관련된 질환의 예방 및 치료를 위한 셀레노갈락토시드 화합물 및 이의 용도
JP2019523245A (ja) オーファン核内受容体Ｎｕｒ７７のリガンド及びその使用
CN102532110B (zh) 喹唑啉衍生物及其作为细胞凋亡抑制剂的用途
Li et al. Design and synthesis of glycyrrhetinic acid glycosides against acute lung injury and pulmonary fibrosis
US20200239512A1 (en) Methods of preventing or treating atherosclerosis with inhibitors of specific isoenzymes of human neuraminidase
JP2020515633A (ja) ヘパラン硫酸糖模倣物化合物並びにその医薬品及び薬用化粧品としての使用
CN121941693A (zh) 化合物及其用途
WO2026099533A1 (es) Tratamiento del síndrome de dificultad respiratoria aguda (sdra) con inhibidores de gpbp1

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160118

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160118

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170307

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170516

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170608

R150 Certificate of patent or registration of utility model

Ref document number: 6158840

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees